智通财经APP获悉，科笛-B(02487)涨超10%，截至发稿，涨10.11%，报7.19港元，成交额577.63万港元。
消息面上，近期，科笛集团宣布，原研进口4%盐酸米诺环素泡沫剂（安佐清®）首批商业化产品正式从科笛无锡工厂发往全国各地。作为全球首款且唯一的外用4%盐酸米诺环素泡沫剂，适用于9岁及以上儿童和成人患者的非结节性中度至重度寻常痤疮炎症性病变的局部治疗。此外，10月17日，科笛集团宣布原研进口非那雄胺喷雾剂（商品名：纷永维®Finjuve®）首批商业化产品正式从上药国际供应链有限公司发往全国各地。10月20日，在中国正式开启销售。
财通证券指出，公司是泛皮肤病治疗新星，两大核心产品具备较强差异化优势，伴随商业化逐步落地有望为公司注入业绩增长动能。开源证券认为，公司已形成覆盖毛发疾病、皮肤护理和医美领域的多元化产品布局，看好密集管线落地和商业化进程加速下的成长空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.